WO1994006463A1 - Immortalized cells and uses therefor - Google Patents
Immortalized cells and uses therefor Download PDFInfo
- Publication number
- WO1994006463A1 WO1994006463A1 PCT/US1993/008606 US9308606W WO9406463A1 WO 1994006463 A1 WO1994006463 A1 WO 1994006463A1 US 9308606 W US9308606 W US 9308606W WO 9406463 A1 WO9406463 A1 WO 9406463A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immortalized
- cell
- tick
- antigen
- pathogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0233—Rickettsiales, e.g. Anaplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
Definitions
- This invention relates generally to immortalized primary cells, and, more specifically, to immortalized cell lines useful for the production of antigens and biologically active compounds.
- Continuous or immortalized cell lines which are characterized by the ability to grow indefinitely are valuable as a source of immunogens, a source of new biologically active compounds and for the production and replication of relevant pathogens.
- the ability to establish a culture that will grow indefinitely varies depending on the animal species from which the cells originate. For example, rodent cells routinely generate continuous cell lines, but chicken cells almost never become immortal. Human cells, with the exception of tumor cells, are not good sources of immortalized cell lines.
- Tick cell cultures are of interest for the research and study of tick-borne pathogens and microorganisms.
- Presently available jn vitro primary or continuous tick cell cultures are not capable of long term, consistent maintenance of tick- borne pathogens.
- the invention provides immortalized cultures of primary cells. These cell lines are useful, for example, as antigens in vaccine compositions, as vessels for growth and production of antigens, as diagnostic reagents, and in therapeutic compositions. Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.
- the present invention provides immortalized tick cell lines and an immortalized bovine T cell line.
- Such immortalized cell lines according to this invention are useful as, or in the production of, vaccinal agents, e.g., against ticks, and may provide protection against diseases caused by pathogens, e.g., tick-borne pathogens.
- the term "immortalized cell line” refers to the cells deposited with the American Type Culture Collection (ATCC) as stated below. Immortalized cells of this invention may be clonally expanded by conventional techniques to produce a homogeneous population of progeny cell lines which can be maintained continuously in an appropriate culture medium.
- DGEC-1 tick cell line
- ATCC American Type Culture Collection
- the invention provides an immortalized bovine T cell line, designated Bpbl-Tl (bovine peripheral blood lymphocyte-T cell).
- Bpbl-Tl bovine peripheral blood lymphocyte-T cell
- This immortalized bovine T cell line is useful, inter alia, for T-cell dependent antigen targeting assays, T-cell receptor and antigen recognition studies, adoptive transfer experiments, and in vitro screening of cytokines, antigens and/or other bioresponse modifiers.
- This line has remained stable for over 8 months and was deposited with the ATCC on September 11, 1992 [ATCC Accession No. CRL11120].
- This invention further includes progeny and derivatives of these cell lines, e.g., cells which have been derived from the specific identified cell line by passaging or clonal expansion. All statements made herein relating to the immortalized cell lines of the invention are equally applicable to their progeny and derivatives.
- Immortalized tick cell cultures of this invention are useful for, among other things, growing, jn vitro, tick-borne pathogens, such as Borrelia burpdorferi. the causative agent of Lyme disease, and for producing antigens to these pathogens. These cell lines have also proven useful in maintaining in vitro cultures of A. marginale. Ehrlichia species, and Borrelia burgdorferi.
- the immortalized T cells of the invention are also useful for growing a selected pathogen, as well as for producing antigens to these pathogens. Additionally, the immortalized T cells of the invention are useful for the study of pathogens capable of infecting T cells, e.g. lentiviruses, and the study of T-cell signal transduction.
- the immortalized cells of this invention provide a system for mass production of antigens, e.g., preferably cellular components such as proteins or non- proteinaceous material capable of inducing an immune response directed against a parasite borne pathogen.
- an immortalized cell of the invention may itself produce a biological or therapeutic agent, e.g., a tick cell polypeptide or protein, or another component or fraction of a tick cell which enhances the ability of a vaccine composition containing a selected pathogenic antigen to stimulate a protective immune response in the vaccine.
- a biological or therapeutic agent e.g., a tick cell polypeptide or protein, or another component or fraction of a tick cell which enhances the ability of a vaccine composition containing a selected pathogenic antigen to stimulate a protective immune response in the vaccine.
- the immortalized tick cell lines, AGEC-1 or DGEC-1 when cultured may naturally produce peptides, polypeptides, proteins, or other cellular fractions which are useful as anti-coagulants, anti-inflammatory agents and diuretics, for pharmaceutical and veterinary purposes.
- These exemplary and other agents are among the biological products naturally produced by an immortalized cell of this invention upon culture.
- Appropriate culture conditions to obtain maximum production of such natural products can be determined by one of skill in the art.
- These biological materials may be produced intracellularly and obtained from the cultured tick cell by conventional cell disruption, e.g., lysis, and purification of the material or a cellular fraction containing it from the lysate, based on its chemical identity or biological activity.
- the immortalized cell of the invention may secrete the agent into the media. Methods of isolating and purifying such biological materials or cell fractions are known in the art and may be utilized as desired.
- the present invention provides a method for producing antigens directed against a selected pathogen by infecting an immortalized cell culture of the invention with a selected pathogenic microorganism, e.g., Borrelia burgdorferi. Ehrlichia canis. Anaplasma marginalis. Babesia bovis. Theileria parva.
- the infected immortalized cell may, upon culturing permit the natural replication of the pathogen, and the production of pathogenic proteins in culture.
- Either the pathogen itself, whether it be a virus or microorganism, or desirable proteinaceous materials including subunits, polypeptides, cell fractions, fragments thereof, or other macromolecules such as carbohydrates, lipids, and lipoproteins may be produced in, and isolated from, the immortalized cell culture by conventional biological and genetic engineering techniques. Such proteinaceous and non-proteinaceous materials, including the immortalized cell or pathogen itself, are defined herein as antigens. Alternatively, the pathogens may be co-harvested from the cell culture infected by the pathogen.
- proteinaceous and non-proteinaceous materials produced by the pathogen-infected immortalized cell lines may be include materials produced from the immortalized cell biosynthetic activity.
- Pathogen-produced materials isolated from the cell culture are expected to have use in vaccine compositions. For example, association of such pathogen-produced material with tick cell derived material may provide vaccinal compositions with enhanced ability to stimulate immunity in the vaccinee due to the influence of the tick cell environment upon the development and growth of the pathogen in the tick cell culture.
- the immortalized bovine cell line and products produced therein may be used to enhance vaccine compositions containing bovine pathogens or antigenic materials thereof. These cells and materials may further be of use in aiding identification of bovine antigens and in assaying for bovine cytokine production and activity.
- an alternative embodiment for producing desirable antigens or polypeptides using an immortalized cell line of this invention involves transfecting the cell line with a recombinant molecule containing a heterologous polypeptide or protein having desirable antigenic properties under the control of a suitable regulatory sequence capable of directing the replication and expression thereof in the immortalized cell line.
- the transfected immortalized cell line containing the recombinant molecule is cultured to enable expression of the heterologous protein or polypeptide in the cell line.
- the methods employed in the design of the recombinant molecule, selection of the heterologous protein and regulatory sequences, and incorporation thereof into the cell line are within the skill of the art.
- Exemplary suitable vectors or plasmids for transfecting the immortalized tick cells include those with an operational promotor, including insect viruses, insect recombinant plasmids, Entomopox virus, and arboviruses.
- insect promoters such as polyhedron of baculovirus, spheroidin of entomopox virus, drosophila promoters or arbovirus (Semliki Forest Virus) would produce the best results in the immortalized tick cells.
- vector components for mammalian cells and known vectors may be readily selected by one of skill in the art for use in transfecting the bovine cell line Bpbl-Tl. See, for example, Maniatis et al, cited above.
- a desirable antigen from an immortalized tick cell line of this invention is exemplified below (Example 3).
- Analogous procedures may be employed" to produce antigens in the immortalized bovine cell line of the invention.
- Media and cells from pathogen-infected immortalized cells are generally collected at 24-108 hours post-infection and are used as the source of antigen for immunizations.
- antigen-containing media can be clarified from cell associated material by centrifugation, aliquoted and stored at -20°C until used.
- the pathogen antigenic material may remain associated with any cell material from the immortalized cell and be incorporated into a vaccine.
- Immortalized tick cell produced material in association with the selected pathogen antigen may enhance the immunostimulatory effect of the pathogen antigen.
- All antigen preparations can be quantified for parasite-specific protein (PSP) with ELISA.
- Cell-associated antigen may be prepared by sonication on ice in serum-free media followed by the centrifugation step described above. Protein concentrations are determined by the method of Bradford, Anal. Biochem..22:248 (1976). Sonicated parasite suspensions are adjusted to a final concentration of 10-100 ⁇ g/mL in serum-free media, aliquoted, and stored at -20°C until use.
- the pathogens may express receptors on the cell surface of the immortalized cell of the invention or intracellularly.
- the pathogens are contained intracellularly and released when the immortalized cell is disrupted m vitro or is processed jn vivo by the animal vaccinated with the pathogen-containing immortalized cell. Disruption may be accomplished using known means, e.g. by freeze-thawing or other biochemical or mechanical disruption.
- antigenic portions of the pathogen are purified or left in combination, i.e. the antigens may comprise a mixture of unpurified cellular material, viral subunits or fragments, media, and, optionally an adjuvant, from the immortalized cell in which they are produced and used in a vaccine formulation.
- the antigens produced as described above can be employed in the preparation of a vaccine.
- the vaccine comprises an immunogenic amount of one or more antigen produced by the invention in a form suitable for internal administration.
- Such a vaccine directed against the selected pathogen or parasite, comprises an immunogenic amount of at least one pathogenic antigen which is produced by growing an immortalized cell culture of this invention infected with the selected pathogen, including viruses and microorganisms.
- the pathogenic antigen includes the entire pathogen, desirable subunits, polypeptides, cell fractions or fragments thereof, or desirable non-proteinaceous material.
- the vaccine contains a whole immortalized cell and the pathogen antigen.
- the pathogenic antigen may be expressed in the immortalized cell intracellularly, on the cell surface, or secreted during the natural processing of the cell or a vaccine formulation containing a pathogen-infected immortalized cell by the host.
- a vaccine composition may contain some cellular component of the immortalized cell which is not the whole cell, e.g., an immunogenic protein or polypeptide fragment of the immortalized cell, a subunit non-proteinaceous material, or mixtures thereof.
- a vaccine is designed to protect against a tick.
- a vaccine composition contains an immunogenic amount of an immortalized tick cell of the invention, a cellular fraction, an antigenic protein or fragment of the cell, or other suitable immunogenic fragments of an immortalized cell of the invention.
- the anti-parasite vaccine of the invention may contain both of the immortalized tick cell lines of the invention, or combinations thereof, whether as whole cells, cellular fractions, or only proteinaceous or desirable non-proteinaceous materials from the cells.
- these vaccine compositions may include other conventional anti-parasitic agents suitable for internal administration and/or be administered in connection with other, known tick vaccinal compositions.
- Example 2 illustrates cross-species reactivity with an anti-tick vaccine of the invention.
- the AGEC- 1 and DGEC- 1 immortalized tick cell lines of the present invention and the Bpbl-Tl bovine cell line are used to prepare vaccines with or without incorporated and replicating pathogens (See Example 3) and a pharmaceutically acceptable carrier.
- a tick vaccine the uninfected or non-pathogen associated tick cells are replicated to the desired volume and cell density using large scale cell culture procedures known to those in the art such as (e.g., roller bottles, microcarrier, suspension, hollow fiber, etc.).
- the cells are harvested by standard procedures and concentrated by ultrafiltration or centrifugation.
- the cells are inactivated by 1-3 cycles of freeze-thaw, or heat or suitable chemical inactivation.
- the inactivated cells are then adjuvanted under optimal conditions to provide a suspension of cells and adjuvant.
- the bovine cells may be analogously manipulated for the preparation of a vaccine composition.
- the membrane proteins of the immortalized cells harvested can be fractionated by standard methods to form a vaccine containing only a part of the immortalized cell of the invention alone or in combination with other antigens.
- This vaccine would not need an inactivation step, but may optionally be adjuvanted and administered in the manner described above.
- one of skill in the art can identify desirable immunogenic proteins, peptides, or polypeptides derived from an immortalized cell of the invention for inclusion in a vaccine composition of the invention. Such proteins, peptides, or polypeptides once identified, can be isolated and purified, produced recombinantly, or synthesized by known means.
- Vaccines of this invention may be employed in a method of immunizing humans or animals against a selected pathogen by injecting a vaccine of this invention into the animal.
- a vaccine composition may contain as one of its active ingredients a selected Borrelia antigen produced in cell line AGEC-1 or DGEC-1, and either purified from the cell line or used in association with cellular material from the tick cell line.
- a vaccine is desirably administered to humans and animals to stimulate immunity against Lyme disease or ticks.
- the vaccine comprises Borrelia antigens only
- the vaccinee may develop immunity against the spirochete, the causative agent of Lyme disease.
- the vaccinee also contains tick cell antigenic material, the vaccinee may develop an immune response which destroys the tick before it can transfer the spirochete to the vaccinee.
- a vaccine of this invention can be used to protect against Rocky Mountain spotted fever, Ehrlichiosis, arboviruses, anaplasmosis, theileriosis, babesiosis, cutaneous irritations, and allergic dermatitis, where the antigen produced in the cell line is derived from one of the pathogens causing that condition.
- a vaccine of the invention is formulated to be protective against Lyme disease
- the whole immortalized tick cell, or a cellular fraction or subunit, a tick cell protein or peptide fragment, or combination thereof, from the immortalized cells may provide one vaccine component to stimulate immunity to the tick cell.
- a tick cell vaccine component may be separately administered with a vaccine containing a whole, inactivated pathogenic cell or subunit vaccine prepared from Borrelia.
- the Borrelia antigen does not have to be produced in the immortalized cells. It may be produced in another conventional way and co- administered with an immortalized tick cell component-containing composition.
- Borrelia are grown in the immortalized cells and then the entire immortalized cells and spirochete material are harvested, inactivated, and preferably adjuvanted as described above.
- Another embodiment involves separating the spirochete or spirochete-produced proteins or antigenic fragments from the immortalized cells after growth and preparing the spirochetes or proteinaceous fragments separately from the cells as a vaccine. In this case, the spirochete is inactivated, or a protein isolated and adjuvanted in a similar manner.
- the present invention provides a vaccine useful in preventing infection with any tick-borne pathogen.
- a vaccine composition contains an immortalized tick cell of the invention, or an immunogenic or antigenic fragment thereof, and an antigen directed to the selected pathogen.
- This antigen may be a whole inactivated viral or cellular pathogen, or an antigenic protein, macromolecule or polypeptide thereof.
- an anti-Lyme disease vaccine contains both the immortalized cells and any Borrelia burgdoferi antigen.
- An example of such an antigen is the spirochete, described in Example 9.
- this invention is not limited to an antigen produced in association with the immortalized tick cells of the invention, but the Borrelia antigen may be obtained from other sources.
- An immortalized cell of the invention can also be used as a recombinant vector for expression of a gene from a selected pathogen, e.g., Borrelia.
- a recombinant vector expressing the gene for Borrelia is introduced into the immortalized tick cells.
- the tick cells expressing the gene are harvested as described above, inactivated, adjuvanted, and optimized for stability and efficacy.
- certain Borrelia express outer surface proteins (OSPs) which are capable of differentially distinguishing between Borrelia grown in standard laboratory media and Borrelia passaged through live ticks.
- OSPs outer surface proteins
- genes representing the OSPs from Borrelia vectored by live ticks could be isolated and expressed in an appropriate vector.
- Particularly useful vectors include the Semliki forest virus vector, the baculovirus vector and the entomopox virus vector.
- the immortalized tick cells of the invention, infected with these viruses to produce the desired antigen are processed as whole cell or subunit extracts as described above.
- antigenic proteins produced in association with the immortalized cells of this invention are desirably employed in vaccine compositions.
- an immunogenic amount of an antigenic protein or desirable non-proteinaceous material are mixed with a pharmaceutically acceptable carrier.
- An immunogenic amount of a selected pathogenic antigen is generally between about 0.01 ⁇ g to 10.0 mg antigen, more preferably 0.05 ⁇ g - 1 mg, and may be determined by one of skill in the art depending on the identify of the antigen, pathogen, and host animal.
- An immunogenic amount of the immortalized tick cells is about 10 to 10 , and preferably about 10 cells/dose.
- the total immortalized cell proteinaceous material, cellular fractions, or desirable non-proteinaceous macromolecules is in the range of 0.05 ⁇ g to 1 mg, as described above for the pathogenic antigens above.
- one of skill in the art can make appropriate adjustments depending upon the vaccine.
- stabilizers may be added to the vaccine compositions of the invention.
- Stabilizers are added optionally to provide longer shelf life or enhance the potency of the formulated vaccines of the invention.
- stabilizers, adjuvants, and inactivation agents are optimized to determine the best formulation for efficacy in the target animal.
- Suitable stabilizers, as with the other optional ingredients, are well known to those of skill in the art.
- Such stabilizers include casamino acids, sucrose, gelatin, phenol red, N-Z amine AS, monopotassium glutamate, potassium monophosphate, potassium diphosphate, bovine albumin fraction V, lactose, lactalbumin hydrolysate, dried milk, and heat inactivated serum.
- Suitable pharmaceutically acceptable carriers facilitate administration of the proteins and antigens but are physiologically inert and/or nonharmful.
- Carriers may be selected by one of skill in the art.
- Exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextrin, agar, pectin, peanut oil, olive oil, sesame oil, and water.
- the carrier or diluent includes a time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
- slow release polymer formulations can be used.
- the vaccine compositions of this invention may be incorporated into conventional sustained-release matrices, implant formulations, tablet formulations or injectable sustained release formulations and matrices. Components of such formulations are well known to the art.
- One or more of the above described vaccine components may be admixed or adsorbed with a conventional adjuvant.
- the adjuvant is used as a non-specific irritant to attract leukocytes or enhance an immune response.
- adjuvants include, among others, mineral oil and water, aluminum hydroxide, Amphigen, Avridine, L121/squalene, D-lactide-polylactide/glycoside, pluronic polyols, muramyl dipeptide, killed Bordetella. saponins, saponin-derivatives such as Quil A, and Immune Stimulatory Complexes (ISCOMs).
- Inactivation agents may also be included in the vaccine formulations of the invention. Suitable inactivation agents include formalin, glutaraldehyde, binaryethyleneimine (BEI), beta-propriolactone, and heat, and freeze/thaw techniques. Other suitable agents are well known in the art.
- a desirable dosage of a vaccine of the invention involves the administration of
- the vaccine is preferably administered in two injections intramuscularly or subcutaneously, approximately 2 weeks to 3 months apart to immunize and boost the immune system of the target animal.
- the mode of administration of the vaccines of the invention may be any suitable route, including intradermally, intravenously, intraperitoneally, transdermally, topologically (e.g. by patch ointment) and by implant.
- the specific dose level, mode and timing of administration for any particular animal depends upon a variety of factors including the age, general health and diet of the animal; the species of the animal; and the degree of protection being sought. Of course, the administration can be repeated at suitable intervals, such as annually, if necessary or desirable.
- the volume of the dose may vary from 0.1 to 5 mL of a sterile preparation of an immunogenic amount of the active vaccine component or components to 0.1 to 1 mL in a small animal such as a dog or cat.
- the immune measurements to detect active immunization of the target animal can be determined by testing titers of antibody to cell protein using in vitro detection systems such as ELISA.
- the immortalized cells of the invention may provide significant therapeutic products.
- the appropriate medium and other conditions under which to culture an immortalized cell line of this invention to enable it to produce a desired therapeutic agent can be readily determined by one of skill in the art by conventional techniques.
- Such a therapeutic agent may be secreted directly into the culture medium and isolated by conventional techniques by one of skill in the art.
- the agent can be isolated from a culture lysate of such cells using known techniques.
- the present invention also provides a method of immunizing animals against tick infestation, Lyme disease, and other tick-borne diseases by administering to an animal a vaccine compostion of the invention.
- the vaccine composition of the invention contains an immunogenic amount immortalizing tick cell of the invention, DGEC-1, AGEC-1, progeny or derivatives thereof, or combinations of these cells.
- the vaccine composition of the invention may contain an immunogenic amount of one or more J .
- the vaccine composition of the invention may contain an immunogenic amount of one or more antigen from the pathogen which causes the tick-borne disease produced in, on, or by an immortalized tick cell line of the invention, an immortalized tick cell line of the invention alone or in combination with one or more of the pathogen, or a combination of these.
- the present invention further provides a method of immunizing animals against a selected pathogen, where said pathogen is capable of being grown in association with the immortalized bovine T cells of the invention.
- pathogen is capable of being grown in association with the immortalized bovine T cells of the invention.
- bovine leukemia virus, bovine immunodeficiency virus or other pathogens which infect bovine lymophocytes are anticipated to be suitable pathogens for growth in the Bpbl-Tl immortalized bovine T cells!
- the immortalized cells of the invention also provide a source of diagnostic reagents.
- the DGEC-1 or AGEC-1 immortalized tick cell lines of the invention may be used as diagnostic reagents in an jn vitro assay to detect the presence of a pathogen, particularly a tick- borne pathogen, in a sample of body fluids from an animal suspected of infection.
- pathogens produced in the immortalized cells of the invention, and their protein sequences may also provide diagnostic agents for the pathogen.
- the specificity of the immortalized cell receptors can be used to determine typing of organisms isolated from patients suspected to have been exposed to such organisms. Once the receptor is identified, receptor specific typing can be performed.
- Such a diagnostic assay preferably involves the association of the cell line of the invention with a detectable label and the incubation of this diagnostic reagent with the sample fluids.
- the specificity of the receptors on the immortalized tick cell sof the invention can be used to type organisms isolated from patients suspected of being bitten by a tick. Because the DGEC- 1 cell specifically agglutinates strain 297 of Borrelia burgdorferi. agglutination could be used to type other JL burgdorferi strains.
- Binding of a pathogen to the cells can be detected by a variety of conventional assays, including agglutination, amplification, stimulation of a pathogen antigen, e.g., OSP on Borrelia, and competition binding utilizing a MAb to the pathogen, e.g., Borrelia, or a receptor on an immortalized cell line of the invention.
- a pathogen antigen e.g., OSP on Borrelia
- MAb e.g., a receptor on an immortalized cell line of the invention.
- IL burgdorferi specifically agglutinates after attachment to DGEC-1 cells in vitro, indicating a specific receptor on the IL burgdorferi and DGEC-1 cells.
- the I burgdorferi are induced to replicate.
- agglutination and detachment denotes an activation (synergy) step between IL burgdorferi and DGEC- 1.
- the immortalized cells and/or I burgdorferi may elaborate growth factors in the media.
- Antibodies to a receptor(s) on the immortalized tick cell lines of the invention, DGEC-1 or AGEC-1, may be used in diagnostic assays.
- Conventional techniques for making suitable polyclonal, recombinant, or more desirably, monoclonal antibodies are well known to those of skill in the art [see, e.g., Kohler and Milstein; W. D. Huse et al.. Science. 246:1275-1281 (1988); PCT Patent Publication No. PCT/WO86/01533, published March 13, 1986; British Patent Application No. GB2188638A, published October 7, 1987; Amit ⁇ l -, Science. 221:747-753 (1986); Queen e ., Proc. Nad.
- the antibodies may be associated with individual labels, which are preferably interactive to produce a detectable signal. Most preferably, the signal is visually detectable. For colorimetric detection, a variety of enzyme systems have been described in the art which will operate appropriately.
- Antibodies specific for receptors on DGEC-1 or AGEC-1 may also be used therapeutically as targeting agents to deliver therapeutic compounds. Rather than being associated with a label, such a therapeutic agent employs the antibody linked to an agent or ligand capable of disabling the replicating mechanism of the pathogen. Alternatively, the antibody may block binding of die pathogen to the target cell. Such antibodies may also be useful in therapeutic compositions for treating tick infestations.
- the immortalized cells DGEC-1 derived from the intestinal epithelial tract of Dermacentor andersoni show continuous growth and replication by a budding process, which can result in "chain-like" clusters of cells. Growth characteristics change with increased duration in culture. However, replication rates among gut cells transformed according to this method vary, as does the ease of transformation. At approximately nine months after initiation of cultures, the cell replication rate increased and slight morphological changes occurred. A distinct nucleus became visible for the first time. It is possible that cells required this time to accommodate to culture conditions and to delete transfected DNA, which is not needed for cellular growth and development.
- the DGEC-1 cell line was further characterized by (1) selective attachment by Borrelia burgdorferi (receptor mediator), (2) differential phagocytosis of red blood cells in mixed blood cell populations and (3) induction of immune response in guinea pigs that reduced tick infestation and feeding.
- the line has remained stable for over 15 months.
- this cell line, as well as immortalized intestinal epithelial cells from Amblyomma americanum (AGEC-1), have proven useful in maintaining in vitro cultures of A. marginale. JL burgdorferi. and Ehrlichia species. It is expected that ⁇ ese cell lines will also be useful in maintaining ia vivo cultures of Arboviruses, Babesia, and other tick-bome pathogens.
- Example 2 Immunization of Guinea Pigs with Immortalized Tick Gut cells
- Successful vaccination of guinea pigs with tick gut extracts is always accompanied with a specific antibody titer than can be enhanced upon repeat vaccinations. These antibody titers are normally measured by ELISA tests.
- This example describes the results of vaccination and challenge studies in the guinea pig model and demonstrates production of antibody against the immortalized tick cells that cross react with native tick gut tissue in an ELISA format.
- the continuously growing tick gut cells of the invention were harvested from L-15B complete medium, centrifuged (at 150 x g; 10 minutes), and washed 3x in L- 15B incomplete medium. The cells were then resuspended in L-15B incomplete medium and adjusted to 1.0 x 10 cells/mL.
- One million cells were administered by subcutaneous injection to each guinea pig on days 0 and 14. Each injection was in a volume of 1 mL, and given in a dose divided between two sites. A total of 12 guinea pigs: 6 for Amblyomma americanum cells and 6 for Dermacentor andersoni cells were used.
- the coating for the wells was made up of 5 ⁇ g/mL of gut antigen suspended in carbonate-bicarbonate buffer, loaded 100 ⁇ l/well, and incubated at 4°C overnight. The wells were blocked with 1% bovine serum albumin.
- Serum dilutions (both control and immune) were made from 1:10 to 1:20480.
- the second antibody used was rabbit anti-guinea pig (IgG, H&L) in HRPO, 1:1000 in 1% BSA (PBS, 0.05% Tween-20).
- the substrate was o-phenylene dramine [OPD; Eastman Kodak, Rochester, NY] and the optical density was read at 490 nm.
- OPD Eastman Kodak, Rochester, NY
- Tables 1 and 2 set out die results of an assay performed on guinea pigs immunized with Amblyomma americanum gut cells immortalized by the technique described in Example 5 above.
- the native gut antigen (5 ⁇ g/mL) was 500 ng/well in 100 ⁇ Las determined by enzyme-linked immunosorbent assay, ELISA, using known techniques. Tick gut protein concentrations were determined prior to testing as a standard. Each well was coated identically, each using the same antibody dilution and detector antibody. Labelled antibody was rabbit anti-guinea pig-HRPO (IgG, H&L), 1:1000.
- the pre-immunization titers (ODi6 ⁇ ) of A. americanum antigen were 0.037 and of D,.
- Table 1 represents the determination of antibody response in animals immunized with immortalized A_, americanum cells (AGEC-1) and not challenged with ticks. The time periods indicate the time after inoculation at which the sera was tested.
- the antigen refers to the antigen used in the test.
- the isolated cells were frozen and thawed. Guinea pigs were immunized with this preparation at 0.5 mg per mL per animal. A total of three booster injections were given with a 10 day interval between inoculations.
- animals immunized with the immortalized Dermacentor andersoni gut cells (DGEC-1) developed strong antibody responses.
- the antigen of Table 3 is that used for screening.
- the antibodies generated against freshly prepared tick gut tissue by immunization of guinea pigs were used in immunofluorescence assays to detect reactive epitopes on immortalized tick gut cells maintained in culture for 11 months. These guinea pig antibodies were obtained from animals that were subsequendy challenged with ticks. After collection of sera for immunolocalization, immunized animals were challenged with larvae, nymphs or adults of d e sensitizing species. This immunolocalization data correlates with the protective study results. Table 4 below illustrates the effect on the life cycle patterns of Dermacentor andersoni ticks on control animals and may be compared witii Table 5 which illustrates similar data on animals immunized witii Dermacentor andersoni native gut antigen.
- Tables 6 and 7 below illustrate this effect on Amblyomma americanum and Dermacentor andersoni ticks in animals immunized with Amblyomma americanum gut cells immortalized by the technique described above.
- the red color indicates that the tick guts apparendy disintegrated.
- Tables 8 and 9 below illustrate this effect on Amblyomma americanum and Dermacentor andersoni ticks in animals immunized with immortalized Dermacentor andersoni gut cells obtained by the technique described above.
- Granulocytes were isolated from blood by the method described by Sigma Chemicals using Histopaque 1077 and 1119 in a double gradient method. Isolated granulocytes were washed 2x in L-15B incomplete medium inoculated to gut cells (1.0 x l0 6 cells/mL). Microscopic examination of cultures 2-3 days post infection showed aggregation of PBL/granulocytes around the gut cells. This was very evident in Amblyomma americanum gut cells, since they are big, oval and larger than PBLs/granulocytes. About 2-3 weeks post-inoculation, the contaminated RBC degenerated, PBL/granulocytes showed rough surfaces and numerous granular material was observed in cultures. In addition, Amblyomma cells showed phagocytosis of hemoglobin (appeared red in color).
- the minute bodies increased in number and many of tfiese bodies studded on to the surface of the gut cells, particularly on Amblyomma americanum gut cells.
- Diff-Quick stained culture smears and one micron thin sections showed numerous bodies (lawn of uniform bodies), which were also studded on the surface of the gut cells.
- Serum samples collected from dogs suffering from Ehrlichiosis were used as a source of antibody and used to identify the organisms in cultures by Florescent Antibody Test. Acetone fixed smears of culture were reacted with antibodies to Erhlichia. and tiiese immunoglobulins were localized by fluoroscein isothyocyante (FITC) conjugated anti-canine antibodies.
- FITC fluoroscein isothyocyante
- the spirochetes started attaching to the cells by 24 hours post infection. As the incubation continued, the clumping of cells by spirochetes increased. By 4-5 days post infection, clear entanglement of cells by spirochetes was evident. It was observed that the cell types in the culture, small, round, clear gut cells were attacked by the spirochetes. The large, round, brown color cells may be resistant to spirochete attachment. By 10-12 days post infection, die spirochete sensitive cells were disintegrated and only spirochete resistant cells were present in the culture. By 15 days post infection, the so-called spirochete resistant cells started multiplying and increasing in number. By 20 days post infection, the spirochete resistant cells were seen uniformly throughout the flask.
- Spirochetes also showed multiplication. The number of spirochetes increased. The spirochete resistant cells may provide some growth factors for the multiplication of spirochetes.
- spirochetes were passaged in a new flask containing gut cells. In the first passage, the clumping of the cells was not seen until 4-5 days post infection. In this flask also, the spirochete attachment was seen only with small, round, clear cells. The large, round, brown cells were not affected by spirochetes.
- This organism was obtained from peripheral blood collected from cattle suffering from anaplasmosis or A mar inale-infected cattle in vacutainers containing heparin and which showed 27% parasitemia as determined by blood smear examination.
- the buffy coat of A. marginale was removed by centrifugation and erythrocytes were washed 2x in L-15B incomplete medium.
- the red blood cell ⁇ number was adjusted to 1.0 x 10 cells/ L in L-15B complete medium with all growth factors without antibiotics.
- Flasks containing approximately 5 mL of immortalized Dermacentor andersoni and Amblyomma americanum gut cells were inoculated with 1.0 x 10 cell/mL infected erythrocytes (2 flasks for each cell type). After inoculation, the cells were incubated at about 30°C as described below.
- the gut cells appeared highly granular, contained numerous minute uniform inclusion bodies, and many cells ruptured and released these inclusion bodies into the surrounding medium. Culture samples were collected for transmission electron microscopy for analysis of infected gut cells. Changes were more evident in the Amblyomma cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Insects & Arthropods (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6508223A JPH08502646A (en) | 1992-09-14 | 1993-09-14 | Immortalized cells and their use |
AU51032/93A AU5103293A (en) | 1992-09-14 | 1993-09-14 | Immortalized cells and uses therefor |
EP93920511A EP0749319A1 (en) | 1992-09-14 | 1993-09-14 | Immortalized cells and uses therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94487392A | 1992-09-14 | 1992-09-14 | |
US07/944,873 | 1992-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994006463A1 true WO1994006463A1 (en) | 1994-03-31 |
Family
ID=25482205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/008606 WO1994006463A1 (en) | 1992-09-14 | 1993-09-14 | Immortalized cells and uses therefor |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0749319A1 (en) |
JP (1) | JPH08502646A (en) |
AU (2) | AU5103293A (en) |
CA (1) | CA2144651A1 (en) |
WO (1) | WO1994006463A1 (en) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998037177A1 (en) * | 1997-02-20 | 1998-08-27 | Mississippi State University | Isolated viable parasite intestinal cells |
WO2000040716A2 (en) | 1999-01-07 | 2000-07-13 | Zymogenetics, Inc. | Soluble receptor br43x2 and methods of using them for therapy |
WO2005087810A2 (en) | 2004-03-08 | 2005-09-22 | Zymogenetics, Inc. | Dimeric fusion proteins and materials and methods for producing them |
EP1988102A1 (en) | 1998-12-07 | 2008-11-05 | ZymoGenetics, Inc. | Growth factor homolog ZVEGF3 |
WO2008157263A2 (en) | 2007-06-15 | 2008-12-24 | Arkansas State University | Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same |
EP2105446A2 (en) | 1998-09-23 | 2009-09-30 | ZymoGenetics, Inc. | Cytokine receptor zalpha11 |
EP2130919A1 (en) | 2001-11-05 | 2009-12-09 | ZymoGenetics, Inc. | IL-21 antagonists |
EP2194130A1 (en) | 1999-12-23 | 2010-06-09 | ZymoGenetics, L.L.C. | Cytokine ZCYTO18 |
US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
US7772365B2 (en) | 1999-01-07 | 2010-08-10 | Zymogenetics, Inc. | Soluble receptor BR43x2 |
EP2230299A1 (en) | 2002-01-18 | 2010-09-22 | ZymoGenetics, Inc. | Novel cytokine ZCYTOR17 ligand |
EP2251352A1 (en) | 2003-08-07 | 2010-11-17 | ZymoGenetics, L.L.C. | Homogeneous preparations of IL-28 and IL-29 |
US7842292B2 (en) | 2005-08-09 | 2010-11-30 | Ares Trading S.A. | Methods for treating B-cell malignancies using a TACI-Ig fusion molecule |
EP2258725A2 (en) | 2000-06-26 | 2010-12-08 | ZymoGenetics, L.L.C. | Cytokine receptor zcytor17 |
EP2264175A1 (en) | 1996-10-16 | 2010-12-22 | ZymoGenetics, L.L.C. | Fibroblast growth factor homologs |
EP2295455A1 (en) | 2002-04-19 | 2011-03-16 | ZymoGenetics, L.L.C. | Cytokine receptor |
EP2295577A2 (en) | 1999-03-09 | 2011-03-16 | ZymoGenetics, Inc. | Human cytokine as ligand of the z-alpha receptor and uses thereof |
EP2338910A1 (en) | 2002-01-18 | 2011-06-29 | ZymoGenetics, Inc. | Cytokine receptor Zcytor17 multimers |
EP2377876A1 (en) | 2006-06-02 | 2011-10-19 | Wyeth LLC | Use of proteins and peptides of the TGF-BETA superfamily for purification and therapeutic methods |
EP2389944A1 (en) | 2004-07-29 | 2011-11-30 | ZymoGenetics, L.L.C. | Use of IL-28 and IL-29 to treat cancer |
WO2011156356A1 (en) | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
US8137678B2 (en) | 2006-11-03 | 2012-03-20 | Intervet Inc. | Canine lyme disease vaccine |
EP2604279A1 (en) | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
EP2623112A1 (en) | 2008-06-27 | 2013-08-07 | Zymogenetics, Inc. | Soluble hybrid Fc gamma receptors and related methods |
WO2013116771A1 (en) | 2012-02-01 | 2013-08-08 | Synthetic Genomics, Inc. | Materials and methods for the synthesis of error-minimized nucleic acid molecules |
US8784812B2 (en) | 2006-05-15 | 2014-07-22 | Zymogenetics, Inc. | Methods for treating autoimmune diseases using a TACI-Ig fusion molecule |
US8808696B2 (en) | 2005-08-09 | 2014-08-19 | Ares Trading S.A. | Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules |
WO2017044424A1 (en) | 2015-09-08 | 2017-03-16 | Theripion, Inc. | Apoa-1 fusion polypeptides and related compositions and methods |
WO2018136163A2 (en) | 2016-12-09 | 2018-07-26 | Theripion, Inc. | Tandem apoa-1 fusion polypeptides |
US10150801B1 (en) | 2017-12-27 | 2018-12-11 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
WO2019016402A1 (en) | 2017-07-20 | 2019-01-24 | Aptevo Research And Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
WO2019120232A1 (en) | 2017-12-20 | 2019-06-27 | Harbour Biomed (Shanghai) Co., Ltd | Antibodies binding ctla-4 and uses thereof |
WO2019132765A1 (en) | 2017-12-27 | 2019-07-04 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
US10675332B1 (en) | 2019-08-26 | 2020-06-09 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
WO2021040610A1 (en) | 2019-08-26 | 2021-03-04 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
WO2021262081A1 (en) | 2020-06-22 | 2021-12-30 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and combinations for use in the treatment of cancer |
WO2022178090A2 (en) | 2021-02-19 | 2022-08-25 | Theripion, Inc. | Dnase fusion polypeptides and related compositions and methods |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4447537A (en) * | 1981-01-22 | 1984-05-08 | The United States Of Americas As Represented By The Department Of Health And Human Services | Tick cell lines |
US5186933A (en) * | 1986-12-30 | 1993-02-16 | Baylor College Of Medicine | Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL84574A (en) * | 1986-11-27 | 1994-10-07 | Biotech Australia Pty Ltd | Antigen from cattle tick, parts, homologues and epitopes thereof having similar immunological activity, process for preparing them, polynucleotide encoding them, vaccines containing them, antibodies derived therefrom and method for protecting animals against tick infestation |
-
1993
- 1993-09-14 JP JP6508223A patent/JPH08502646A/en active Pending
- 1993-09-14 WO PCT/US1993/008606 patent/WO1994006463A1/en not_active Application Discontinuation
- 1993-09-14 EP EP93920511A patent/EP0749319A1/en not_active Withdrawn
- 1993-09-14 AU AU51032/93A patent/AU5103293A/en not_active Abandoned
- 1993-09-14 CA CA002144651A patent/CA2144651A1/en not_active Abandoned
-
1997
- 1997-12-11 AU AU48314/97A patent/AU4831497A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4447537A (en) * | 1981-01-22 | 1984-05-08 | The United States Of Americas As Represented By The Department Of Health And Human Services | Tick cell lines |
US5186933A (en) * | 1986-12-30 | 1993-02-16 | Baylor College Of Medicine | Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system |
Non-Patent Citations (15)
Title |
---|
ACTA PATHOLOGICA ET MICROBIOLOGICA SCANDINAVICA, Volume 82B, issued June 1974, M.P. ANDREASEN, "Multiplication of Cowdria Ruminantium in Monolayer of Tick Cells", pages 455-456. * |
AMERICAN JOURNAL OF VETERINARY RESEARCH, Volume 50, No. 12, issued December 1989, R.J. HIDALGO et al., "Infectivity and Antigenicity of Anaplasma Marginale from Tick Cell Culture", pages 2033-2036. * |
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, Volume 79, No. 5, issued October 1985, S.K. WIKEL, "Resistance to Ixodid Tick Infestation Induced by Administration of Tick-Tissue Culture Cells", pages 513-518. * |
EXPERIMENTAL AND APPLIED ACAROLOGY, Volume 15, No. 3, issued September 1992, A.M. JANSE VAN VUUREN et al., "The Identification of a Shared Immunogen Present in the Salivary Glands and Gut of Ixodid and Argasid Ticks", pages 205-210. * |
IMMUNOLOGY, Volume 69, No. 2, issued February 1990, H. TAKAMATSU et al., "Characterization of Long-Term Cultured Bovine CD4-Positive and CD8-Positive T-Cell Lines and Clones", pages 293-297. * |
INFECTION AND IMMUNITY, Volume 58, No. 4, issued April 1990, M.E. BRANDT et al., "Immunogenic Integral Membrane Proteins of Borrelia Burgdorferi are Lipoproteins", pages 983-991. * |
JOURNAL OF IMMUNOLOGICAL METHODS, Volume 128, Number 2, issued 17 April 1990, E.J. GLASS et al., "Generation and Characterization of Bovine Antigen-Specific T Cell Lines", pages 267-275. * |
JOURNAL OF THE NATIONAL CANCER INSTITUTE, Volume 30, No. 4, issued April 1963, I. MACPHERSON, "Characterization of a Hamster Cell Clone Transformed by Polyoma Virus", pages 795-813. * |
MEDICAL SCIENCE RESEARCH, Volume 15, issued 1987, S.K. WIKEL et al., "Immunization Induced Resistance to Amblyomma Americanum Infestation: Tick Gut Derived Antigens", pages 543-544. * |
NATURE, Volume 284, issued 03 April 1980, "Transforming Activity of DNA of Chemically Transformed and Normal Cells", pages 418-421. * |
PROTEIN EXPRESSION AND PURIFICATION, Volume 1, issued 1990, J.J. DUNN et al., "Outer Surface Protein (OspA) from the Lyme Disease Spirochete, Borrelia Burgdorferi: High Level Expression and Purification of a Soluble Recombinant Form of OspA", pages 159-168. * |
See also references of EP0749319A4 * |
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, Volume 14, issued 1987, R.J. SCIBIENSKI, "Establishment and Initial Characterization of Continuous In Vitro Cultures of Bovine T Lymphocytes", pages 209-222. * |
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, Volume 23, Number 3-4, issued December 1989, M.J. ROMANO et al., "Phenotypic Characterization of Bovine Lymphoblastoid Cell Lines", pages 293-307. * |
VETERINARY PARASITOLOGY, Volume 14, issued, 1984, S.K. WIKEL, "Immunomodulation of Host Responses to Ectoparasite Infestation-An Overview", pages 321-339. * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2339002A1 (en) | 1996-10-16 | 2011-06-29 | ZymoGenetics, Inc. | Fibroblast growth factor homologs |
EP2264175A1 (en) | 1996-10-16 | 2010-12-22 | ZymoGenetics, L.L.C. | Fibroblast growth factor homologs |
WO1998037177A1 (en) * | 1997-02-20 | 1998-08-27 | Mississippi State University | Isolated viable parasite intestinal cells |
US6017757A (en) * | 1997-02-20 | 2000-01-25 | Mississippi State University | Isolated viable nematode intestinal cells |
EP2105446A2 (en) | 1998-09-23 | 2009-09-30 | ZymoGenetics, Inc. | Cytokine receptor zalpha11 |
EP1988102A1 (en) | 1998-12-07 | 2008-11-05 | ZymoGenetics, Inc. | Growth factor homolog ZVEGF3 |
US7772365B2 (en) | 1999-01-07 | 2010-08-10 | Zymogenetics, Inc. | Soluble receptor BR43x2 |
WO2000040716A2 (en) | 1999-01-07 | 2000-07-13 | Zymogenetics, Inc. | Soluble receptor br43x2 and methods of using them for therapy |
EP2256199A1 (en) | 1999-01-07 | 2010-12-01 | ZymoGenetics, Inc. | Therapeutic uses of BR43X2 soluble receptors |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
EP2295577A2 (en) | 1999-03-09 | 2011-03-16 | ZymoGenetics, Inc. | Human cytokine as ligand of the z-alpha receptor and uses thereof |
EP2194130A1 (en) | 1999-12-23 | 2010-06-09 | ZymoGenetics, L.L.C. | Cytokine ZCYTO18 |
EP2258725A2 (en) | 2000-06-26 | 2010-12-08 | ZymoGenetics, L.L.C. | Cytokine receptor zcytor17 |
EP2130919A1 (en) | 2001-11-05 | 2009-12-09 | ZymoGenetics, Inc. | IL-21 antagonists |
EP2338910A1 (en) | 2002-01-18 | 2011-06-29 | ZymoGenetics, Inc. | Cytokine receptor Zcytor17 multimers |
EP2230299A1 (en) | 2002-01-18 | 2010-09-22 | ZymoGenetics, Inc. | Novel cytokine ZCYTOR17 ligand |
EP2840089A1 (en) | 2002-01-18 | 2015-02-25 | ZymoGenetics, Inc. | Cytokine receptor zcytor17 multimers |
EP2295455A1 (en) | 2002-04-19 | 2011-03-16 | ZymoGenetics, L.L.C. | Cytokine receptor |
EP2251352A1 (en) | 2003-08-07 | 2010-11-17 | ZymoGenetics, L.L.C. | Homogeneous preparations of IL-28 and IL-29 |
EP2251353A1 (en) | 2003-08-07 | 2010-11-17 | ZymoGenetics, L.L.C. | Homogeneous preparations of IL-28 and IL-29 |
WO2005087810A2 (en) | 2004-03-08 | 2005-09-22 | Zymogenetics, Inc. | Dimeric fusion proteins and materials and methods for producing them |
EP2389944A1 (en) | 2004-07-29 | 2011-11-30 | ZymoGenetics, L.L.C. | Use of IL-28 and IL-29 to treat cancer |
US7842292B2 (en) | 2005-08-09 | 2010-11-30 | Ares Trading S.A. | Methods for treating B-cell malignancies using a TACI-Ig fusion molecule |
US8808696B2 (en) | 2005-08-09 | 2014-08-19 | Ares Trading S.A. | Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules |
US8784812B2 (en) | 2006-05-15 | 2014-07-22 | Zymogenetics, Inc. | Methods for treating autoimmune diseases using a TACI-Ig fusion molecule |
EP2377876A1 (en) | 2006-06-02 | 2011-10-19 | Wyeth LLC | Use of proteins and peptides of the TGF-BETA superfamily for purification and therapeutic methods |
US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
US8414901B2 (en) | 2006-11-03 | 2013-04-09 | Intervet Inc. | Canine Lyme disease vaccine |
US8137678B2 (en) | 2006-11-03 | 2012-03-20 | Intervet Inc. | Canine lyme disease vaccine |
WO2008157263A2 (en) | 2007-06-15 | 2008-12-24 | Arkansas State University | Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same |
EP2604280A2 (en) | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
EP2604279A1 (en) | 2008-03-27 | 2013-06-19 | ZymoGenetics, Inc. | Compositions and methods for inhibiting PDGFRBETA and VEGF-A |
EP2623112A1 (en) | 2008-06-27 | 2013-08-07 | Zymogenetics, Inc. | Soluble hybrid Fc gamma receptors and related methods |
WO2011156356A1 (en) | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
US8822642B2 (en) | 2010-06-09 | 2014-09-02 | Zymogenetics, Inc. | Dimeric fusion proteins and related compositions and methods |
EP3597764A2 (en) | 2012-02-01 | 2020-01-22 | SGI-DNA, Inc. | Material and methods for the synthesis of error-minimized nucleic acid molecules |
WO2013116771A1 (en) | 2012-02-01 | 2013-08-08 | Synthetic Genomics, Inc. | Materials and methods for the synthesis of error-minimized nucleic acid molecules |
WO2017044424A1 (en) | 2015-09-08 | 2017-03-16 | Theripion, Inc. | Apoa-1 fusion polypeptides and related compositions and methods |
WO2018136163A2 (en) | 2016-12-09 | 2018-07-26 | Theripion, Inc. | Tandem apoa-1 fusion polypeptides |
WO2019016402A1 (en) | 2017-07-20 | 2019-01-24 | Aptevo Research And Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
WO2019120232A1 (en) | 2017-12-20 | 2019-06-27 | Harbour Biomed (Shanghai) Co., Ltd | Antibodies binding ctla-4 and uses thereof |
EP4295915A2 (en) | 2017-12-20 | 2023-12-27 | Harbour Biomed (Shanghai) Co., Ltd | Antibodies binding ctla-4 and uses thereof |
US10351607B1 (en) | 2017-12-27 | 2019-07-16 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
WO2019132765A1 (en) | 2017-12-27 | 2019-07-04 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
US10323071B1 (en) | 2017-12-27 | 2019-06-18 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
US10370421B2 (en) | 2017-12-27 | 2019-08-06 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
US10301364B1 (en) | 2017-12-27 | 2019-05-28 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
US10150801B1 (en) | 2017-12-27 | 2018-12-11 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
US10675332B1 (en) | 2019-08-26 | 2020-06-09 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
WO2021040610A1 (en) | 2019-08-26 | 2021-03-04 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and methods of use thereof |
WO2021262081A1 (en) | 2020-06-22 | 2021-12-30 | Imunami Laboratories Pte. Ltd. | Recombinant polypeptides and combinations for use in the treatment of cancer |
WO2022178090A2 (en) | 2021-02-19 | 2022-08-25 | Theripion, Inc. | Dnase fusion polypeptides and related compositions and methods |
WO2022178078A1 (en) | 2021-02-19 | 2022-08-25 | Theripion, Inc. | Paraoxonase fusion polypeptides and related compositions and methods |
Also Published As
Publication number | Publication date |
---|---|
EP0749319A4 (en) | 1996-09-16 |
EP0749319A1 (en) | 1996-12-27 |
JPH08502646A (en) | 1996-03-26 |
CA2144651A1 (en) | 1994-03-31 |
AU5103293A (en) | 1994-04-12 |
AU4831497A (en) | 1998-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0749319A1 (en) | Immortalized cells and uses therefor | |
Williams et al. | Immunological and biological characterization of Coxiella burnetii, phases I and II, separated from host components | |
Rapp et al. | SV40-adenovirus" hybrid" populations: transfer of SV40 determinants from one type of adenovirus to another. | |
Gottstein et al. | Antigenic variation in Giardia lamblia: cellular and humoral immune response in a mouse model | |
US4816253A (en) | Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
Doyle | Antigenic variation in the salivarian trypanosomes | |
US4596707A (en) | Babesia parasite antigen useful in vaccine and diagnostic reagent | |
US4567041A (en) | Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent | |
JPH10501682A (en) | Cytotoxic T cell epitope | |
TWI228419B (en) | Neospora vaccine | |
US8034571B1 (en) | Microbial polynucleotides expressed during infection of a host | |
Lewis, BD*, Penzhorn, BL** & Lï¿ ½pez Rebollar | Immune responses to South African Babesia canis and the development of a preliminary vaccine | |
Finlay et al. | The use of the complement fixation test for rapid typing of infectious pancreatic necrosis virus | |
US7033748B2 (en) | Identification of microbial polynucleotides expressed during infection of a host | |
US4759927A (en) | Vaccine against Potomac horse fever and method of preparation therefore | |
Uchida et al. | Immunofluorescence test with Rickettsia montana for serologic diagnosis of rickettsial infection of the spotted fever group in Shikoku, Japan | |
Kimura et al. | Rapid, simple serological diagnosis of infectious pancreatic necrosis by coagglutination test using antibody-sensitized staphylococci | |
US4457915A (en) | Babesiosis vaccine prepared from soluble parasitic antigen factors isolated from disintegration of Babesia infected erythrocites | |
US11623945B2 (en) | Immunostimulating compositions and uses therefore | |
RU2341288C1 (en) | MEDICINE FORMING CELLULAR IMMUNITY FOR MYCOBACTERIUM TUBERCULOSIS H37 Rv, METHOD OF PRODUCTION THEREOF (VERSIONS), RECOMBINANT STRAIN AND TUBERCULOSIS DIAGNOSTIC AGENT | |
CN109880839A (en) | Porcine mycoplasmal pneumonia and pig circular ring virus bigeminy recombinant vaccine preparation method | |
WO1983000017A1 (en) | Anaplasma antigen | |
WO1990002567A1 (en) | Virus-derived antigenic composition and its preparation and use | |
Deol et al. | The influence of gamma inulin and Algammulin on the immune response in sheep to a recombinant antigen of Taenia ovis | |
Doyle | Antigenic variation in the haemoprotozoa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2144651 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993920511 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1995 403846 Country of ref document: US Date of ref document: 19950720 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1993920511 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993920511 Country of ref document: EP |